The Messenger, Not the Message: Rethinking Eosinophils as Biomarkers for Biologic Therapy in COPD

Blood eosinophil counts have become the entry criterion for biologic therapy in chronic obstructive pulmonary disease (COPD). However, the eosinophil-selected programmes produced mixed results, and the 2026 alarmin trials reduced exacerbations without any eosinophil threshold. We re-read the published primary and subgroup estimates of 16 randomised trials and asked whether eosinophil gradients behave as predictive or merely prognostic markers. Within populations already enriched at 300 cells/µL, higher counts did not consistently predict larger effects: the rate ratio for counts of 500 cells/µL or more versus fewer was 0.51 versus 0.80 in BOREAS but 0.70 versus 0.65 in NOTUS. In contrast, exhaled nitric oxide of 20 ppb or more was associated with a larger dupilumab effect in the same direction in both trials (pooled approximate interaction p = 0.009). Tozorakimab reduced exacerbations across all eosinophil strata, with a gradient (0.77 to 0.57; approximate interaction p = 0.077) that is suggestive but statistically inconclusive. Astegolimab showed no modification by eosinophils or smoking status. We propose that blood eosinophils are a downstream messenger of an upstream epithelial–alarmin endotype rather than the therapeutic target itself. Blood eosinophils remain a simple and useful marker of risk and enrichment, but selection may need to move from a single-cell threshold to composite endotypes that combine exposure history, airway biomarkers and structural traits. Further studies are warranted, designed to test treatment-by-biomarker interactions prospectively.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/jcm15229069
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Messenger, Not the Message: Rethinking Eosinophils as Biomarkers for Biologic Therapy in COPD

Angelo Coppola, Simone Ielo, Alexandru Corlăteanu, Pier‐Valerio Mari et al.
Journal of Clinical Medicine
Chronic Obstructive Pulmonary Disease (COPD) Research
article

The Messenger, Not the Message: Rethinking Eosinophils as Biomarkers for Biologic Therapy in COPD

Angelo Coppola, Simone Ielo, Alexandru Corlăteanu, Pier‐Valerio Mari, Lorenzo Carriera
article en

Abstract

Blood eosinophil counts have become the entry criterion for biologic therapy in chronic obstructive pulmonary disease (COPD). However, the eosinophil-selected programmes produced mixed results, and the 2026 alarmin trials reduced exacerbations without any eosinophil threshold. We re-read the published primary and subgroup estimates of 16 randomised trials and asked whether eosinophil gradients behave as predictive or merely prognostic markers. Within populations already enriched at 300 cells/µL, higher counts did not consistently predict larger effects: the rate ratio for counts of 500 cells/µL or more versus fewer was 0.51 versus 0.80 in BOREAS but 0.70 versus 0.65 in NOTUS. In contrast, exhaled nitric oxide of 20 ppb or more was associated with a larger dupilumab effect in the same direction in both trials (pooled approximate interaction p = 0.009). Tozorakimab reduced exacerbations across all eosinophil strata, with a gradient (0.77 to 0.57; approximate interaction p = 0.077) that is suggestive but statistically inconclusive. Astegolimab showed no modification by eosinophils or smoking status. We propose that blood eosinophils are a downstream messenger of an upstream epithelial–alarmin endotype rather than the therapeutic target itself. Blood eosinophils remain a simple and useful marker of risk and enrichment, but selection may need to move from a single-cell threshold to composite endotypes that combine exposure history, airway biomarkers and structural traits. Further studies are warranted, designed to test treatment-by-biomarker interactions prospectively.

Journal of Clinical MedicineVol. 15(22)
Università Cattolica del Sacro Cuore (IT), Azienda Ospedaliera di Perugia (IT), ASL Roma (IT), Saint Camillus International University of Health and Medical Sciences (IT), Ospedale San Filippo Neri (IT), Nicolae Testemițanu State University of Medicine and Pharmacy (MD), Ospedale San Donato (IT)
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon